Does the magnitude of mitral regurgitation determine hemodynamic response to vasodilation in chronic congestive heart failure?
Although it is usually assumed that direct-acting vasodilators improve cardiac function in patients with congestive heart failure (CHF) by altering left ventricular preload and afterload, several studies have suggested that most of the benefit occurs as a result of a reduction in associated mitral regurgitation (MR), which is present in the majority of patients with severe CHF. To test his hypothesis, the hemodynamic response to oral hydralazine was examined in CHF patients with competent mitral prostheses (group 1) and patients with CHF due to severe MR and left ventricular dysfunction (group 2). Both groups demonstrated significant increases in cardiac, stroke volume, and stroke work indices, although these were greater in group 2. Only group 2 experienced a significant reduction in left ventricular filling pressure. Thus, the presence of MR is not essential for hemodynamic improvement but is associated with significantly greater responses.